BioAge Labs (NASDAQ:BIOA) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a strong sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the stock. Roth Capital reiterated a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. BTIG Research reissued a “buy” rating and issued a $40.00 target price on shares of BioAge Labs in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Needham & Company LLC lowered their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Finally, Jefferies Financial Group set a $21.00 price target on BioAge Labs in a research note on Friday, July 31st. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BioAge Labs presently has an average rating of “Moderate Buy” and an average target price of $36.57.

BioAge Labs Price Performance

Shares of BioAge Labs stock opened at $9.59 on Friday. The firm has a market capitalization of $440.18 million, a P/E ratio of -4.03 and a beta of 0.94. The company has a 50 day moving average price of $16.19 and a 200 day moving average price of $17.74. BioAge Labs has a 52 week low of $4.58 and a 52 week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The company had revenue of $2.45 million for the quarter. As a group, research analysts anticipate that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Institutional Trading of BioAge Labs

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in BioAge Labs in the second quarter valued at $69,831,000. Jupiter Topco LLC purchased a new position in shares of BioAge Labs during the 2nd quarter valued at about $52,597,000. Janus Henderson Group PLC raised its stake in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of BioAge Labs in the 4th quarter valued at about $13,892,000. Finally, Walleye Capital LLC acquired a new position in shares of BioAge Labs in the 2nd quarter valued at about $8,686,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.